MDM2 and ovarian carcinoma: In order to evaluate the potential impact of MDM2 del1518 status on endometrial and ovarian cancer risk, we evaluated the OR by comparing the frequency of the MDM2 del1518 genotypes observed in ovarian and endometrial cancer cases to the SNP status among the 1,872 healthy female controls.